How to access Joenja from the UAE — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
A UAE patient with a confirmed diagnosis of Activated PI3K-delta Syndrome (APDS) may receive a prescription for Joenja (leniolisib) from their treating clinical immunologist or haematologist. Joenja is FDA-approved, manufactured by Pharming Group, and is the first therapy specifically indicated for APDS — a rare primary immunodeficiency driven by gain-of-function variants in PIK3CD or PIK3R1, causing recurrent infections, lymphoproliferation, and (often) lymphoma predisposition. In the UAE, Joenja is not locally registered, which is why your immunologist is likely guiding you toward the Ministry of Health and Prevention (MoHAP) named-patient import pathway.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Joenja is a selective PI3K-delta inhibitor taken as a twice-daily oral tablet. Eligibility is based on genetic confirmation of APDS via accredited genetic testing for a pathogenic variant in PIK3CD (APDS1) or PIK3R1 (APDS2), alongside a clinical phenotype typical of APDS (recurrent respiratory infections, lymphoproliferation, hypogammaglobulinaemia, autoimmune cytopenias). Treatment requires an immunologist familiar with APDS and ongoing monitoring including infection surveillance, lymph-node imaging, and immunoglobulin replacement coordination where relevant. Because Joenja is oral, in-country administration is straightforward once the prescribing plan is in place.
Is Joenja legally importable into the UAE?
Yes — through the MoHAP named-patient import framework. Parallel authority operates in Abu Dhabi through the Department of Health (DoH) and in Dubai through the Dubai Health Authority (DHA), depending on where the prescribing facility is located.
The named-patient mechanism allows a UAE-licensed physician to import a medicine not locally registered when: (a) the medicine is approved by a recognised reference authority such as the US FDA, (b) no clinically equivalent locally registered alternative is available, (c) the physician takes clinical responsibility, and (d) chain of custody is documented end to end. For APDS in the UAE, there is no locally registered disease-specific alternative, making the clinical rationale direct once genetic diagnosis is confirmed.
How the pathway works, step by step
- Consultation with your clinical immunologist. Genetic confirmation of APDS (PIK3CD or PIK3R1 pathogenic variant), clinical phenotype documentation, baseline infection and lymphoproliferation history, and Joenja clinical rationale prepared.
- Treatment-centre identification. A UAE tertiary immunology centre with experience in primary immunodeficiency is confirmed as the treating site.
- MoHAP named-patient application. Your physician or the hospital pharmacy files the application with clinical rationale, genetic report, patient reference, and chain-of-custody plan.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure Joenja from authorised distribution.
- Shipment. Joenja ships with chain-of-custody documentation to the treating hospital pharmacy.
- Arrival and dispensing. The hospital pharmacy releases the supply with dosing instructions; the immunology team schedules infection, imaging, and laboratory surveillance.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming APDS diagnosis, genetic report (PIK3CD or PIK3R1), clinical phenotype, and Joenja as the indicated treatment
- Verification of their UAE medical licence
- A copy of the accredited genetic diagnostic report
- Patient identifier (anonymised reference where possible)
- An administration and monitoring plan including infection surveillance, imaging, and any continuing immunoglobulin replacement coordination
Reserve Meds provides a physician documentation kit with the templates MoHAP (or DoH/DHA) reviewers expect to see for rare-immunodeficiency named-patient imports, including the genotype-gated eligibility documentation central to Joenja.
Costs and timing
Joenja's US cash-pay annual cost sits in an indicative 2026 range of roughly USD 550,000–650,000. International logistics, MoHAP documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first dispense after cohort intake opens is approximately 14–28 days from the moment a complete MoHAP application is submitted. Refills ship on a rolling basis against the monthly dispensing schedule.
Reserve Meds is in pre-launch. Fulfilment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
A culturally-aware note: APDS, as a primary immunodeficiency, is often diagnosed after years of recurrent infections across childhood and adolescence. In UAE families, the diagnostic journey often involves genetic testing abroad and care across multiple specialists — immunology, haematology, pulmonology, and ENT. Our concierge coordination works with the family's designated case contact and ensures continuity across specialists within the UAE and any cross-border follow-up the family maintains.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Joenja specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Regulatory package for your physician and for MoHAP (or DoH/DHA) review.
- Logistics. Chain-of-custody shipment coordination to the treating hospital pharmacy.
- Concierge case lead. A named point of contact for the patient and family, managing ongoing refill logistics.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating immunologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in the UAE? Yes, when executed through the MoHAP (or DoH/DHA) named-patient framework with appropriate documentation. See our trust and compliance page.
Is Joenja a cure? No. Joenja is a targeted therapy that reduces lymphoproliferation and improves immunological function in APDS by inhibiting the hyperactive PI3K-delta pathway. Your immunologist will discuss realistic outcome expectations.
Can my child take Joenja? FDA labelling covers patients aged 12 years and older. Your immunologist will confirm age-based eligibility.
Does Joenja replace immunoglobulin replacement therapy? Not necessarily. Many APDS patients continue immunoglobulin replacement alongside Joenja; your immunology team decides the combined regimen.
Will insurance cover this? Cash-pay is the default. Some UAE insurers consider rare-disease imports case by case; we supply documentation for submission but do not process insurance claims directly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Joenja coordination in the UAE.
Add me to the Joenja waitlistComposite case examples. Reserve Meds is in pre-launch. This content is for general information and does not constitute medical advice.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.